-transparent.png){kind=logo}
In a double blind trial, 28 male chronic schizophrenic in-patients received either pimozide, given once weekly, or fluphenazine decanoate, given mostly once fortnightly. There was no difference in relapse rates over nine months. However, three-quarters of the patients on pimozide who completed the trial developed at least mild tardive dyskinesia. All patients on pimozide lost weight, the average loss being 5.4 kg (12 lbs). Plasma pimozide levels suggested satisfactory drug compliance. Plasma prolactin levels confirmed that in the pimozide group there was fluctuating dopamine receptor antagonism, while in the fluphenazine group average plasma prolactin levels throughout most of the interval between injections were at the upper limit of normal.
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
December 1980,
The British journal of psychiatry : the journal of mental science,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
September 1987,
The British journal of psychiatry : the journal of mental science,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
January 1987,
Progress in neuro-psychopharmacology & biological psychiatry,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
January 1982,
Acta psychiatrica Belgica,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
July 1981,
Indian journal of psychiatry,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
December 1985,
Singapore medical journal,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
October 1986,
Ceskoslovenska psychiatrie,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
May 1976,
The New Zealand medical journal,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
February 1978,
Psychological medicine,
R McCreadie, and
M Mackie, and
D Morrison, and
J Kidd
January 1979,
Current medical research and opinion,
